Physician profile
Qing Jia
NPI 1609805506
$59,402.31
in general payments reported to CMS, 2019-2025
56 companies · $3,855 in 2025
The $3,855 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,215 · 2020: $5,752 · 2021: $5,315 · 2022: $26K · 2023: $6,544 · 2024: $7,117 · 2025: $3,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,150 · Travel and Lodging: $581 · Education: $105 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,620.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,150.00 |
| Travel and Lodging | $581.24 |
| Education | $104.52 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $13,875.16 | 2020-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $13,208.37 | 2021-2025 | |
| Grt US Holding, INC. | $4,861.11 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $4,734.42 | 2019-2023 | Farxiga |
| Valeritas, INC. | $4,171.12 | 2019 | |
| Novo Nordisk INC | $2,349.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,830.95 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Medtronic Minimed, INC. | $1,316.35 | 2019-2020 | |
| Medtronic, INC. | $1,221.71 | 2022-2024 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $959.36 | 2020-2025 | |
| Insulet Corporation | $956.51 | 2020-2025 | Omnipod |
| Abbvie INC. | $876.47 | 2020-2025 | |
| Abbott Laboratories | $673.91 | 2020-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $641.32 | 2020-2025 | Jardiance |
| Ibsa Pharma INC. | $637.23 | 2020-2025 | Tirosint, Licart, Flector |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $627.69 | 2020-2025 | Korlym |
| Cequr Corporation | $536.74 | 2022-2025 | Cequr Simplicity |
| Zealand Pharma US, INC. | $499.74 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $496.24 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $448.34 | 2019-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $406.64 | 2020-2025 | Evenity, Prolia, Tepezza |
| Radius Health, INC. | $381.39 | 2020-2025 | Tymlos |
| Sequel Med Tech, LLC | $353.69 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $336.38 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $273.45 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Esperion Therapeutics, INC. | $271.75 | 2020-2023 | Nexletol |
| Merck Sharp & Dohme LLC | $234.48 | 2020-2021 | |
| Intuity Medical INC | $188.88 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Astellas Pharma US INC | $175.35 | 2025 | Veozah |
| Amneal Pharmaceuticals LLC | $164.58 | 2020-2024 | Unithroid |
| Pfizer INC. | $155.42 | 2021-2025 | |
| Madrigal Pharmaceuticals | $150.02 | 2025 | Rezdiffra |
| Averitas Pharma INC. | $143.52 | 2023 | Qutenza |
| Recordati_rare_diseases_inc. | $132.37 | 2021-2025 | Isturisa, Signifor Lar |
| Amarin Pharma, INC. | $130.06 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $128.97 | 2019 | |
| Avvisto Therapeutics, LLC | $105.14 | 2025 | Cycloset |
| Amphastar Pharmaceuticals, INC. | $71.43 | 2024-2025 | |
| Lifescan, INC. | $70.66 | 2020-2023 | |
| Currax Pharmaceuticals LLC | $66.80 | 2023 | Nexletol, Nexlizet, Onzetra Xsail |
| Neurocrine Biosciences, INC. | $60.38 | 2025 | |
| Ascensia Diabetes Care US INC. | $59.90 | 2021-2024 | |
| Ultragenyx Pharmaceutical INC. | $58.73 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $56.44 | 2023-2025 | Yorvipath |
| Verity Pharmaceuticals INC. | $48.57 | 2024-2025 | Tlando |
| Nevro Corp. | $40.45 | 2022 | |
| Renalytix Ai, INC. | $38.66 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Arbor Pharmaceuticals, INC. | $37.65 | 2020 | |
| Companion Medical, INC. | $37.53 | 2020 | |
| Amryt Pharma Holdings LTD | $20.07 | 2023 | Mycapssa |
| Endo Pharmaceuticals INC. | $17.87 | 2020 | |
| Alfasigma USA, INC. | $16.10 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.64 | 2023 | Cycloset |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.60 | 2019 | |
| Eisai INC. | $12.57 | 2021 | |
| Janssen Biotech, INC. | $6.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qing Jia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.